2m 2m 2m 2m 2m 2m 2m
RELMADA THERAPEU (RLMD)
NASDAQ
$6.33-$0.005 (-0.08%)
Price as of Jun 03, 2026 7:03 PM EDT- $756.3MMarket Cap
- 757.84%1-Year Change
- BiotechnologyIndustry
RELMADA THERAPEU (RLMD)
$6.33-$0.005 (-0.08%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 319,048 -16.41% | 381,661 -92.23% | 4.9M +328.79% | -2.1M +4,342.23% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 319,048 -16.41% | 381,661 -92.23% | 4.9M +328.79% | -2.1M +4,342.23% | |
Sales and Marketing Expense | 200.0M N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -26.9M -41.79% | -46.2M -15.75% | -54.8M -51.64% | -113.3M +25.05% | |
Depreciation and Amortization Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Operating Expenses | 59.1M -29.55% | 83.9M -19.10% | 103.7M -35.69% | 161.2M +28.28% | |
Operating Profit | -59.1M -29.55% | -83.9M -19.10% | -103.7M -35.69% | -161.2M +28.28% | |
Interest Income | 1.4M -60.45% | 3.5M N/A | N/A N/A | 6.4M N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 1.4M -60.45% | 3.5M N/A | 0 -100.00% | 6.4M N/A | |
Total Nonoperating Income and Expense | 1.7M -56.16% | 3.9M -20.34% | 4.9M +16.77% | 4.2M +8,803.46% | |
Income before Taxes | -59.1M -29.55% | -83.9M -19.10% | -103.7M -35.69% | -161.2M +28.28% | |
Income Taxes | 4,425 N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -57.4M -28.25% | -80.0M -19.04% | -98.8M -37.09% | -157.0M +24.88% | |
Net Income from Continuing Operations Applicable to Common | -57.4M -28.25% | -80.0M -19.04% | -98.8M -37.09% | -157.0M +24.88% | |
Basic EPS and Net Income | -1.45 -45.28% | -2.65 -19.21% | -3.28 -38.11% | -5.30 -25.98% | |
Diluted EPS and Net Income | -1.45 -45.28% | -2.65 -19.21% | -3.28 -38.11% | -5.30 -25.98% | |
Basic Weighted Average Shares | 39.5M +30.88% | 30.2M +0.21% | 30.1M +1.59% | 29.6M +68.80% | |
Diluted Weighted Average Shares | 39.5M +30.88% | 30.2M +0.21% | 30.1M +1.59% | 29.6M +68.80% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 3.5M -9.35% | 3.9M -5.73% | 4.1M -24.17% | 5.4M -87.86% | |
Short-Term Investments | 89.5M +118.04% | 41.1M -55.49% | 92.2M -35.47% | 142.9M -14.65% | |
Cash and Cash Equivalents and Short-Term Investments | 93.0M +107.10% | 44.9M -53.38% | 96.3M -35.06% | 148.3M -30.01% | |
Total Current Assets | 94.0M +105.22% | 45.8M -53.03% | 97.5M -36.21% | 152.9M -31.54% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Assets | 19,500 -11.26% | 21,975 -49.04% | 43,125 +23.66% | 34,875 +23.26% | |
Total Assets | 94.0M +105.17% | 45.8M -53.03% | 97.6M -36.20% | 152.9M -31.53% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | 4.0M N/A | N/A N/A | |
Total Current Liabilities | 6.4M -37.52% | 10.3M -15.61% | 12.2M -2.20% | 12.5M -17.21% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Liabilities | 7.5M -27.24% | 10.3M -15.57% | 12.2M -2.20% | 12.5M -17.21% | |
Retained Earnings | -698.3M +8.95% | -640.9M +14.26% | -560.9M +21.38% | -462.1M +51.48% | |
Total Stockholders Equity | 86.5M +143.55% | 35.5M -58.38% | 85.4M -39.22% | 140.4M -32.57% | |
Total Shares Outstanding | 73.3M +143.03% | 30.2M +0.25% | 30.1M 0.00% | 30.1M +8.50% | |
Cash Flow | |||||
Cash from Operating Activities | -45.8M -11.53% | -51.8M +0.19% | -51.7M -50.23% | -103.8M +12.98% | |
Capital Expenditures | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Investing Activities | -48.1M -193.36% | 51.6M +2.20% | 50.5M +155.67% | 19.7M +136.46% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 93.6M +232,034.78% | -40,341 -59.03% | -98,463 -100.22% | 45.0M -76.05% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -18,523.92% -15.73% | -21,980.51% +940.83% | -2,111.83% -128.11% | 7,512.70% -97.11% | |
Return on Assets | -82.08% -26.43% | -111.57% +41.43% | -78.89% -5.50% | -83.48% +13.36% | |
Return on Equity | -94.05% -28.93% | -132.33% +51.22% | -87.51% -2.85% | -90.07% +12.40% | |
Revenue Growth | -16.41% -82.21% | -92.23% -128.05% | 328.79% +107.57% | -4,342.23% +4,095.58% | |
Current Ratio | 14.62 +228.44% | 4.45 -44.35% | 8.00 -34.78% | 12.26 -17.31% | |
Cash Ratio | 0.54 +45.06% | 0.37 +11.71% | 0.34 -22.46% | 0.43 -85.34% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow